Total cardiovascular disease
Beta‐blockers probably leads to higher total cardiovascular disease compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Stroke
Beta‐blockers probably leads to higher total stroke compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Total coronary heart disease
Beta‐blockers showed no clear difference in total coronary heart disease compared with calcium‐channel blockers (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
Beta‐blockers showed no clear difference in withdrawal due to adverse effect compared with calcium‐channel blockers (low certainty).
1 finding from 1 review
Marginal bone level change · Adults with missing teeth who received osseointegrated root-formed oral implants, functionally loaded and followed for at least 1 year
MegaGen EZ Plus blasted standard implants showed no clear difference in marginal bone level change compared with megaGen EZ Plus calcium-incorporated (Xpeed) implants; GRADE not reported.
1 finding from 1 review
Implant failure · Adults with missing teeth who received osseointegrated root-formed oral implants, functionally loaded and followed for at least 1 year
1 finding from 1 review
Bone formation rate um(2)/mm(2)/d · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Fall in bone formation rate % · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
PTH · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
ALP U/L · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Serum phosphorus · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Increase in volume of more than 10% compared to the pretreatment measurement · Patients with histologically confirmed CGCG in one or both jaws and normal serum calcium and parathyroid hormone (PTH) levels
Calcitonin (salmon calcitonin nasal spray 200 IU/day) showed no clear difference in increase in volume of more than 10% compared to the pretreatment… compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events · Patients with histologically confirmed CGCG in one or both jaws and normal serum calcium and parathyroid hormone (PTH) levels
1 finding from 1 review
Adverse events were not described separately for each group. Trialists reported that adverse events were in most patients minimal and consisted of nausea, flushes and some dizziness. One patient had diarrhoea which…
1 study · 14 participants
GRADE not reported
Death · kidney transplant recipients
ACE Inhibitors showed no clear difference in death compared with calcium channel blockers (low certainty).
1 finding from 1 review
Graft loss · kidney transplant recipients
ACE Inhibitors showed no clear difference in graft loss compared with calcium channel blockers (low certainty).
1 finding from 1 review
GFR · kidney transplant recipients
1 finding from 1 review
Acute rejection · kidney transplant recipients
It is very uncertain whether ACE Inhibitors changes acute rejection compared with calcium channel blockers (very low certainty).
1 finding from 1 review
Proteinuria · kidney transplant recipients
1 finding from 1 review
Haemoglobin (g/dL) · kidney transplant recipients
1 finding from 1 review
Blood loss: post‐treatment haematocrit (%) · kidney transplant recipients
1 finding from 1 review